# US 2014/0155681 A1 · Shielding of magnetic field as a medical therapy > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0155681 A1 - Document ID: US20140155681A1 - Status: Published application - Kind: A1 - Application number: 14/093,187 - Filed: 2013-11-29 - Published: 2014-06-05 - Earliest claimed: 2012-11-29 - Assignees: Micromed Scientia, Inc. - Applicants: Micromed Scientia, Inc. - Inventors: Jiu Xiang NI - Web page: https://patentgrep.com/patent/US20140155681A1 ## CPC - A61N 2/004: {specially adapted for a specific therapy} - A61N 2/002: {in combination with another treatment} - C12N 13/00: Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves - G01N 33/502: {for testing non-proliferative effects} - G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis - A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract Provided are methods for disrupting dipolar interactions in vivo and in vitro, as wells as treating conditions associated with abnormal cell growth, by subjecting to an artificial, stable magnetic field. Also provided are assays involving an artificial, stable magnetic field. Additionally, the exposure of an artificial, stable magnetic field may be combined with other non-magnetic therapy in treatment or assays. ## Claims ### Claim 1 A method for disrupting dipolar molecular interactions in a cell comprising subjecting the cell to an artificial, stable magnetic field for a period of time sufficient to result in altered dipolar interactions between molecules in said cell so as to alter the cellular physiology. ### Claim 2 (depends on 1) The method of claim 1, wherein the period of time is at least 18 hours, at least 24 hours, at least 48 hours, or at least 72 hours. ### Claim 3 (depends on 1) The method of claim 1, wherein the cell is a rapidly dividing cell. ### Claim 4 (depends on 3) The method of claim 3, wherein the rapidly dividing cell is a cancer cell. ### Claim 5 (depends on 1) The method of claim 1, wherein the cell is an injured cell. ### Claim 6 (depends on 1) The method of claim 1, wherein the artificial, stable magnetic field is provided by magnetic shielding. ### Claim 7 (depends on 1) The method of claim 1, where in the artificial, stable magnetic filed is provided by a magnetic field stabilization. ### Claim 8 A method for reducing undesired cell proliferation in a mammal which method comprises placing said mammal in an artificial, stable magnetic field which alters the physiology of proliferative cells thereby reducing their rate of proliferation. ### Claim 9 A method for inhibiting tumor metastasis in a mammal which method comprises placing said mammal in an artificial, stable magnetic field for a period of time sufficient to alter the physiology of cells undergoing undesired proliferation at a secondary site that is different from the primary site of said mammal thereby reducing the rate of undesired cell proliferation at the secondary site. ### Claim 10 A device for mammalian therapy comprising an artificial, stabilized magnetic field, wherein said device permits said mammal to experience the artificial stabilized magnetic field for a therapeutically effective time. ### Claim 11 (depends on 10) The device of claim 10, wherein said device is stationary or portable. ### Claim 12 (depends on 11) The device of claim 11, wherein said device is a portable device which is attachable to at least a portion of a mammalian body, wherein said device creates an artificial, stabilized magnetic field to at least a portion of the mammalian body. ### Claim 13 An assay for ascertaining the optimal condition of an artificial magnetic field therapy to maximize the therapeutic results for pathological cell growth, wherein said assay comprising: (a) isolating pathological cells from a mammal for in vitro culturing; (b) subjecting cell culture(s) of step (a) to a plurality of artificial magnetic fields wherein each of said artificial magnetic fields is maintained under different conditions from said other artificial magnetic fields; (c) comparing the growth of cell cultures in each of said artificial magnetic fields; (d) optionally repeating steps (a) through (c); and (e) determining the optimal condition of said artificial magnetic field based on the results of steps (a) through (d). ### Claim 14 (depends on 13) The assay of claim 13, wherein the optimal condition minimizes the adverse effects associated with the therapy. ### Claim 15 A method for developing an in vivo personalized treatment comprising: (a) conducting an in vitro assay for ascertaining the optimal condition of an artificial magnetic field therapy to maximize the therapeutic results for pathological cell growth, wherein the assay comprises: (i) isolating pathological cells from a mammal for in vitro culturing; (ii) subjecting cell culture(s) of step (i) to a plurality of artificial magnetic fields wherein each of said artificial magnetic fields is maintained under different conditions from said other artificial magnetic fields; (iii) comparing the growth of cell cultures in each of said artificial magnetic fields; (iv) optionally repeating steps (i) through (iii); and (v) determining the optimal condition of said artificial magnetic field based on the results of steps (i) through (iv); (b) correlating the optimal condition based on the in vitro assay and the condition of the in vivo treatment. ### Claim 16 A method for evaluating the therapeutic effect of a non-magnetic treatment for reducing undesired cell proliferation in a mammal which method comprises: (a) administering said non-magnetic treatment to said mammal; (b) placing said mammal in an artificial, stable magnetic field which alters the physiology of proliferative cells before, during, or after administration of said non-magnetic treatment; (c) comparing the growth of undesired cells before step (a) with the growth of undesired cells after step (b) to select the non-magnetic treatment that results in reduced growth of undesired cells after step (b). ### Claim 17 (depends on 16) The method of claim 16, wherein said non-magnetic treatment is selected from the group consisting of chemotherapy, radiation therapy, thermotherapy, and monoclonal antibody therapy. ### Claim 18 (depends on 16) The method of claim 16, wherein undesired cell proliferation is reduced by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or about 100%, after the treatment. ### Claim 19 An in vitro assay for an anti-tumor agent comprising: (a) isolating pathological cells from a mammal for in vitro culturing; (b) culturing cell culture(s) of step (a) in the presence of said anti-tumor agent under the condition of being subjected to an artificial, stable magnetic field and under the condition of being free of said magnetic field; (c) comparing the growth of cell cultures under each condition; (d) selecting the anti-tumor agent which causes more cell death under the condition of being subjected to said magnetic field than under the condition of being free of said magnetic field. ### Claim 20 A method for determining a reduced effective dose of an anti-tumor agent comprising: (a) isolating pathological cells from a mammal for in vitro culturing; (b) culturing cell culture(s) of step (a) in the presence of said anti-tumor agent at various doses under the condition of being subjected to an artificial, stable magnetic field and under the condition of being free of said magnetic field; (c) comparing the growth of cell cultures treated with various doses of said anti-tumor agent under each condition; (d) determining a dose of said anti-tumor agent under the condition of being subjected to an artificial, stable magnetic field, which dose achieves the same reduction in cell growth but is lower than the dose under the condition of being free of said magnetic field. ### Claim 21 (depends on 20) The method of claim 20, wherein the anti-tumor agent is selected from the group consisting of a chemotherapy, a radiation therapy, a thermotherapy, and a monoclonal antibody therapy.